Recent Advances in the Biology of Human Circulating Tumour Cells and Metastasis

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2016 Nov 16

PMID 27843628

Citations 21

Authors

Sofia Gkountela

Barbara Szczerba

Cinzia Donato

Nicola Aceto

Affiliations

Soon will be listed here.

Abstract

The development of a metastatic disease is recognised as the cause of death of over 90% of patients diagnosed with cancer. Understanding the biological features of metastasis has been hampered for a long time by the difficulties to study widespread cancerous lesions in patients, and by the absence of reliable methods to isolate viable metastatic cells during disease progression. These difficulties negatively impact on our ability to develop new agents that are tailored to block the spread of cancer. Yet, recent advances in specialised devices for the isolation of circulating tumour cells (CTCs), hand-in-hand with technologies that enable single cell resolution interrogation of their genome and transcriptome, are now paving the way to understanding those molecular mechanisms that drive the formation of metastasis. In this review, we aim to summarise some of the latest discoveries in CTC biology in the context of several types of cancer, and to highlight those findings that have a potential to improve the clinical management of patients with metastatic cancer.

Citing Articles

A deep learning model predicts the presence of diverse cancer types using circulating tumor cells.

Albaradei S, Alganmi N, Albaradie A, Alharbi E, Motwalli O, A Thafar M Sci Rep. 2023; 13(1):21114.

PMID: 38036622 PMC: 10689793. DOI: 10.1038/s41598-023-47805-2.

Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer.

Grasic Kuhar C, Silvester J, Mencinger M, Ovcaricek T, Cemazar M, Miceska S Cancers (Basel). 2023; 15(13).

PMID: 37444507 PMC: 10340574. DOI: 10.3390/cancers15133397.

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC.

Goh K, Cheng T, Tham S, Lim D Biomedicines. 2023; 11(2).

PMID: 36831044 PMC: 9953588. DOI: 10.3390/biomedicines11020508.

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer.

Rzhevskiy A, Kapitannikova A, Butnaru D, Shpot E, Joosse S, Zvyagin A Biomedicines. 2022; 10(12).

PMID: 36551871 PMC: 9776104. DOI: 10.3390/biomedicines10123115.

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma.

Frundt T, von Felden J, Krause J, Heumann A, Li J, Riethdorf S Front Oncol. 2022; 12:941660.

PMID: 36439492 PMC: 9685781. DOI: 10.3389/fonc.2022.941660.

References

Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K . Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol. 2000; 156(1):57-63. PMC: 1868645. DOI: 10.1016/S0002-9440(10)64706-2. View

Went P, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G . Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004; 35(1):122-8. DOI: 10.1016/j.humpath.2003.08.026. View

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View

Pao W, Miller V, Politi K, Riely G, Somwar R, Zakowski M . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2(3):e73. PMC: 549606. DOI: 10.1371/journal.pmed.0020073. View

Gray-Schopfer V, Wellbrock C, Marais R . Melanoma biology and new targeted therapy. Nature. 2007; 445(7130):851-7. DOI: 10.1038/nature05661. View

Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-43. DOI: 10.1126/science.1141478. View

Zheng S, Lin H, Liu J, Balic M, Datar R, Cote R . Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A. 2007; 1162(2):154-61. DOI: 10.1016/j.chroma.2007.05.064. View

10.

Danila D, Heller G, Gignac G, Gonzalez-Espinoza R, Anand A, Tanaka E . Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(23):7053-8. DOI: 10.1158/1078-0432.CCR-07-1506. View

11.

Nagrath S, Sequist L, Maheswaran S, Bell D, Irimia D, Ulkus L . Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450(7173):1235-9. PMC: 3090667. DOI: 10.1038/nature06385. View

12.

Husemann Y, Geigl J, Schubert F, Musiani P, Meyer M, Burghart E . Systemic spread is an early step in breast cancer. Cancer Cell. 2008; 13(1):58-68. DOI: 10.1016/j.ccr.2007.12.003. View

13.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

14.

Maheswaran S, Sequist L, Nagrath S, Ulkus L, Brannigan B, Collura C . Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-77. PMC: 3551471. DOI: 10.1056/NEJMoa0800668. View

15.

Klein C . Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9(4):302-12. DOI: 10.1038/nrc2627. View

16.

Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C . Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat. 2009; 118(3):523-30. DOI: 10.1007/s10549-009-0461-7. View

17.

Miller M, Doyle G, Terstappen L . Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol. 2009; 2010:617421. PMC: 2793426. DOI: 10.1155/2010/617421. View

18.

Stott S, Lee R, Nagrath S, Yu M, Miyamoto D, Ulkus L . Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2(25):25ra23. PMC: 3141292. DOI: 10.1126/scitranslmed.3000403. View

19.

Stott S, Hsu C, Tsukrov D, Yu M, Miyamoto D, Waltman B . Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010; 107(43):18392-7. PMC: 2972993. DOI: 10.1073/pnas.1012539107. View

20.

Duda D, Duyverman A, Kohno M, Snuderl M, Steller E, Fukumura D . Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010; 107(50):21677-82. PMC: 3003109. DOI: 10.1073/pnas.1016234107. View